Understanding how genetics affect GLP-1 response in Mexican-Americans with prediabetes
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
This study is trying to see how genetics affect how well GLP-1 therapy works for Mexican-Americans with prediabetes, to help create better, personalized treatments.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Brownsville, Texas) |
| Trial ID | NCT05119179 on ClinicalTrials.gov |
What this trial studies
This project investigates the genetic and transcriptomic factors that influence individual responses to glucagon-like peptide-1 (GLP-1) therapy in Mexican-Americans diagnosed with prediabetes. By analyzing genetic variants and their effects on GLP-1 response, the study aims to develop personalized treatment strategies for managing prediabetes and related metabolic conditions. The research will involve RNA sequencing and the assessment of single nucleotide polymorphisms (SNPs) to uncover mechanisms that dictate treatment efficacy. This approach seeks to improve therapeutic outcomes in a population that is often underrepresented in clinical research.
Who should consider this trial
Good fit: Ideal candidates for this study are Mexican-American adults aged 18 and older who have been diagnosed with prediabetes and are at high risk for progression to diabetes.
Not a fit: Patients who do not have prediabetes or those who are not of Mexican-American descent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatments for prediabetes and related metabolic disorders in Mexican-American patients.
How similar studies have performed: While there have been studies on GLP-1 responses in other populations, this specific focus on Mexican-Americans and the genetic mechanisms involved is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: 1. Men and women, ages 18 years and older 2. Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting glucose of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood glucose of 140-199 mg/dL after 75-gram oral glucose challenge), and/or a hemoglobin A1C ranging from 5.7% to 6.4% 3. High risk for progression to diabetes: defined as having at least one of the two following additional factors: Obesity (BMI ≥ 30 kg/m2) and/or metabolically unhealthy status. "Metabolically unhealthy status" is defined as at least two of the following: elevated blood pressure (SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg), elevated triglycerides ≥ 150 mg/dL, low HDL cholesterol (males \< 40 mg/dL; females \< 50 mg/dL), and elevated fasting glucose ≥ 100 mg/dL (Wu S et al., 2017). 4. Women of childbearing age must agree to use an acceptable method of pregnancy prevention (barrier methods, abstinence, hormonal contraception, intrauterine contraception, or surgical sterilization) for the duration of the study. 5. Patients must have the following laboratory values: Hematocrit ≥ 34 vol%, estimated glomerular filtration rate ≥ 60 mL/min per 1.73 m2, AST (SGOT) \< 2.5 times ULN, ALT (SGPT) \< 2.5 times ULN, alkaline phosphatase \< 2.5 times ULN Exclusion Criteria: 1. History of Type 1 or Type 2 diabetes mellitus 2. Pregnant or breastfeeding women 3. Medications: metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, thiazolidinediones, insulin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and/or corticosteroids over the last 3 months. 4. Active malignancy 5. History of clinically significant cardiac, hepatic, pancreatic or renal disease. 6. History of any serious hypersensitivity reaction to the study medication (or any other incretin mimetic) 7. Prisoners or subjects who are involuntarily incarcerated 8. Prior history of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2) 9. Family history of medullary thyroid cancer (a rare form of thyroid cancer) or MEN2. However, as many individuals may not be aware of the specific type of thyroid cancer, will also exclude any family history of thyroid cancer or MEN2. 10. Hospitalization for COVID-19 in last 3 months
Where this trial is running
Brownsville, Texas
- UTHealth Clinical Research Unit (CRU) at UT Brownsville — Brownsville, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Absalon D Gutierrez, MD — The University of Texas Health Science Center, Houston
- Study coordinator: Norma Perez-Olazaran
- Email: Norma.P.PerezOlazaran@uth.tmc.edu
- Phone: (956) 755-0695
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.